NACC1 Mouse Monoclonal Antibody

NACC1 Mouse Monoclonal Antibody

Cat: AMM80923
Size1:50μL Price1:$168
Size2:100μL Price2:$300
Application:IHC,ELISA

Reactivity:Human
Conjugate:Unconjugated
Optional conjugates: Biotin, FITC (free of charge).
See other 26 conjugates.

Gene Name:NACC1
Category: Mouse Monoclonal Antibody Tags: , , , ,

Summary

Production Name

NACC1 Mouse Monoclonal Antibody

Description

Mouse Monoclonal Antibody

Host

Mouse

Application

IHC,ELISA

Reactivity

Human

 

Performance

Conjugation

Unconjugated

Modification

Unmodified

Isotype

Mouse IgG1

Clonality

Monoclonal Antibody

Form

Liquid

Storage

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Buffer

Purified antibody in PBS with 0.05% sodium azide.

Purification

Affinity Purification

 

Immunogen

Gene Name

NACC1

Alternative Names

NAC1; BEND8; NAC-1; BTBD14B; FLJ37383; NACC1

Gene ID

112939

SwissProt ID

Q96RE7

 

Application

Dilution Ratio

IHC:1:200-1:1000,ELISA:1:10000

Molecular Weight

58kDa

 

Background

NAC1 or nuclear accumbens-1 is a nuclear factor that belongs to the POZ/BTB (Pox virus and zinc finger/bric-a-brac tramtrack broad complex) domain family. Also known as BTBD14B, it was originally identified in a unique neuronal forebrain structure responsible for reward motivation and addictive behaviors . NAC1 recruits HDAC3 and HDAC4 to transcriptionally repress gene expression in neuronal cells (3) and specifically co-represses other POZ/BTB proteins in the central nervous system . NAC1 is upregulated in several tumor types, including breast, renal cell, and hepatocellular carcinoma, as well as high grade ovarian serous carcinoma, where it has long been suspected as a chemoresistance gene . The chemoresistance mechanism reportedly occurs through NAC1 negative regulation of the GADD45 pathway . NAC1 has also been described as part of the extended transcriptional network in pluripotent cells that involves Oct-4, Sox2, Nanog, Sall1, KLF4 and Sall4 . Tissue specificity: Overexpressed in several types of carcinomas including ovarian serous carcinomas. Expression levels positively correlate with tumor recurrence in ovarian serous carcinomas, and intense immunoreactivity in primary ovarian tumors predicts early recurrence. Up-regulated in ovarian carcinomas after chemotherapy, suggesting a role in development of chemotherapy resistance in ovarian cancer .

 

Research Area